Iambic Therapeutics files for Nasdaq IPO to fund cancer drug development
- Iambic Therapeutics files for Nasdaq IPO under ticker IAM
- Nvidia holds 9.6 million shares pre-offering
- Proceeds to fund three cancer drug candidates
- FY25 revenue rose to $9.4 million from $1.2 million
- Net loss widened to $77.3 million in FY25
*this image is generated using AI for illustrative purposes only.
Iambic Therapeutics Inc., an AI drug discovery company backed by Nvidia Corp. (NASDAQ: NVDA) and Qatar Investment Authority, filed for an initial public offering with the SEC on Monday.
The Delaware-based firm plans to list on the Nasdaq Global Select Market under the ticker "IAM". Proceeds from the offering will be used to advance three cancer drug candidates through clinical development, with remaining funds allocated to general operating costs.
Key Filing Details
The S-1 filing, dated September 21, 2026, does not disclose the number of shares to be offered or an expected price range. J.P. Morgan, Jefferies, BofA Securities, and Citigroup are underwriting the offering.
According to the filing, Nvidia Corporation beneficially owned 9.6 million shares of Iambic Therapeutics prior to the offering.
| Entity | Shareholding | Status |
|---|---|---|
| Nvidia Corporation | 9.6 million shares | Beneficial owner pre-offering |
Business Overview
Founded in 2019, Iambic combines proprietary AI models with automated lab experiments in an approach it calls "molecular superintelligence." The company has raised roughly $461.8 million in capital since its founding through September 18, 2026. Its five largest shareholders include Catalio, Nexus Ventures, Q Healthcare Holding, Nvidia, and Coatue Ventures.
Iambic holds partnerships with major pharmaceutical firms including AbbVie Inc. (NYSE: ABBV), Takeda Pharmaceutical Company Limited (NYSE: TAK), and Jazz Pharmaceuticals PLC (NASDAQ: JAZZ).
Pipeline Progress
The company’s lead drug candidate is an experimental cancer pill designed to target tumors driven by the HER2 protein, which is currently in early human trials. Two additional cancer drug candidates remain in earlier lab-stage testing. Iambic plans to seek FDA clearance to begin human trials on both by the end of the year.
Financial Performance
Iambic’s full-year 2025 revenue was $9.4 million, up from $1.2 million in 2024. However, its net loss widened to $77.3 million from $47.9 million over the same period.
What the Numbers Show
While revenue grew significantly year-over-year, the widening net loss indicates that operational expenses are outpacing top-line growth as the company advances its clinical pipeline. The substantial capital raise of $461.8 million suggests a long runway for development before profitability is expected.
How might the successful IPO of Iambic Therapeutics influence investor appetite for other AI-driven biotech startups seeking public listings?
What are the potential implications for Nvidia's stock valuation if Iambic's clinical trials succeed or fail, given its significant pre-offering shareholding?
Will the widening net losses and high operational expenses deter institutional investors despite the strong revenue growth trajectory?
15
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
